Athira Pharma (NASDAQ:ATHA) Cut to “Neutral” at Mizuho

Mizuho downgraded shares of Athira Pharma (NASDAQ:ATHA) from an outperform rating to a neutral rating in a research note issued to investors on Thursday morning, MarketBeat reports. They currently have $0.50 price objective on the stock, down from their previous price objective of $5.00.

A number of other equities research analysts have also recently commented on ATHA. Rodman & Renshaw cut shares of Athira Pharma from a buy rating to a neutral rating in a report on Wednesday, September 4th. JMP Securities cut Athira Pharma from an outperform rating to a market perform rating in a research report on Wednesday, September 4th. Finally, BTIG Research lowered Athira Pharma from a buy rating to a neutral rating in a report on Wednesday, September 4th.

Athira Pharma Stock Down 7.4 %

Shares of NASDAQ ATHA opened at $0.43 on Thursday. The business has a 50-day moving average price of $2.49 and a 200 day moving average price of $2.49. The stock has a market cap of $16.49 million, a PE ratio of -0.14 and a beta of 2.90. Athira Pharma has a 52-week low of $0.43 and a 52-week high of $4.30.

Athira Pharma (NASDAQ:ATHA) last announced its earnings results on Thursday, August 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.05. Sell-side analysts anticipate that Athira Pharma will post -2.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ATHA. Private Advisor Group LLC acquired a new position in Athira Pharma during the 4th quarter worth approximately $32,000. Rothschild Investment LLC purchased a new position in Athira Pharma in the second quarter worth $34,000. Mirador Capital Partners LP acquired a new stake in Athira Pharma in the first quarter valued at $57,000. XTX Topco Ltd purchased a new stake in shares of Athira Pharma during the 2nd quarter worth $60,000. Finally, Invst LLC acquired a new position in shares of Athira Pharma during the 2nd quarter worth $68,000. 57.12% of the stock is owned by hedge funds and other institutional investors.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.